Clinical Trials Logo

Filter by:
NCT ID: NCT05356546 Completed - Cardiac Disease Clinical Trials

TYRX™ Pocket Health Study

Start date: May 31, 2022
Phase:
Study type: Observational

Medtronic, Inc. is sponsoring the TYRX™ Pocket Health Study to evaluate the histological and morphometric parameters of the device capsule in participants who underwent a cardiovascular implantable electronic device (CIED) procedure with a TYRX™ Absorbable Antibacterial Envelope and are returning for a CIED replacement procedure.

NCT ID: NCT05356533 Completed - Alcohol Drinking Clinical Trials

Coping Skills for Alcohol Use

Start date: April 4, 2022
Phase: N/A
Study type: Interventional

A total of 120 young adults who drink to cope with negative affect will be randomized to a 4-week, web-based intervention with interactive modules on cognitive-behavioral skills (n=60) or an assessment only control (n=60). Participants will complete 4 weekly assessments and a 1- and 3-month follow-up.

NCT ID: NCT05356338 Completed - Obesity, Childhood Clinical Trials

Expanding Health System Intervention Through The Women, Infants and Children (WIC) Program Partnership

WHISPER
Start date: May 25, 2022
Phase: N/A
Study type: Interventional

Pilot test the health system-based intervention to improve family beverage choices and promote water consumption, engaging WIC nutritionists to augment the intervention with follow-up and counseling of families at regularly-scheduled WIC appointments in a small randomized trial among 30 WIC-enrolled families.

NCT ID: NCT05355935 Completed - Healthy Volunteer Clinical Trials

A Study to Investigate the Effects of Brensocatib on QT Interval in Healthy Participants

Start date: April 27, 2022
Phase: Phase 1
Study type: Interventional

The study has 2 Parts: The primary purpose of Part 1 is to determine the supratherapeutic dose of brensocatib to be used in Part 2 of the study. The primary purpose of Part 2 is to assess brensocatib's potential for prolonging the QT interval.

NCT ID: NCT05355805 Completed - Clinical trials for Hidradenitis Suppurativa

Hidradenitis Suppurativa Phase 2b Pivotal Study of Izokibep

Start date: May 5, 2022
Phase: Phase 2
Study type: Interventional

Izokibep is a potent and selective inhibitor of interleukin 17A (IL-17A) that is being developed for treatment of hidradenitis suppurativa (HS). This study will evaluate the efficacy, safety, and immunogenicity of izokibep administered subcutaneously (SC) in adult subjects with moderate to severe HS.

NCT ID: NCT05355402 Completed - Clinical trials for Hypertriglyceridemia

A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Adults With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), and/or With Severe Hypertriglyceridemia

Start date: May 9, 2022
Phase: Phase 2
Study type: Interventional

The purpose of the study is to evaluate the effect of olezarsen on percent change in fasting triglyceride (TG) levels compared to placebo at Months 6 and 12 and the percentage of participants who achieve different thresholds in fasting TG. Another objective is to evaluate the effect of olezarsen on percent change in fasting apolipoprotein C-III (apoC-III), very low-density lipoprotein cholesterol (VLDL-C), remnant cholesterol, non-high-density lipoprotein cholesterol (non-HDL-C), HDL-C, total cholesterol (TC), apolipoprotein B (apoB), low-density lipoprotein cholesterol (LDL-C), and apolipoprotein A-1 (apoA-1).

NCT ID: NCT05354349 Completed - Healthy Clinical Trials

Bioavailability of SC Formulation and Japanese Ethnobridging Study for PRA023

Start date: April 6, 2022
Phase: Phase 1
Study type: Interventional

This is a randomized double-blind, placebo-controlled, single-dose study to evaluate the safety, tolerability, and pharmacokinetics of PRA023 in healthy Caucasian and Japanese adult volunteers

NCT ID: NCT05354115 Completed - COVID-19 Clinical Trials

Sample Collection for Evaluation of the Panbio™ COVID-19/ Flu A&B Rapid Panel.

Start date: March 14, 2022
Phase: N/A
Study type: Interventional

This study is designed as a prospective, multicentric, sample collection study. The collected samples will be used for diagnostic research, product development and validation of the Panbio™ COVID-19/ Flu A&B Rapid Panel for the qualitative detection of COVID-19 antigen, Influenza A antigen (H1N1 and H3N2), and Influenza B antigen in human nasal and nasopharyngeal swabs by the study sponsor, Abbott.

NCT ID: NCT05354050 Completed - Bacterial Vaginosis Clinical Trials

Pharmacokinetic Study of DARE-BV1

Start date: November 3, 2020
Phase: Phase 1
Study type: Interventional

Single-Center, Phase 1, Single-dose PK study of DARE-BV1 (2% clindamycin phosphate vaginal gel, 100mg) under development for the treatment of bacterial vaginosis (BV).

NCT ID: NCT05353296 Completed - Insomnia Clinical Trials

Digital Cognitive-Behavioral Therapy for Insomnia in Spanish Speaking Latinas/os (Dormir Mejor Study)

Start date: April 7, 2022
Phase: N/A
Study type: Interventional

The primary objective of the proposed study is to examine the effectiveness of a culturally adapted digital program of cognitive behavioral therapy for insomnia (CBT-I) compared to minimally enhanced usual care (mEUC) on primary outcomes: reduction in insomnia symptoms at 9 weeks and 6 months post-intervention, using a standard scale among Spanish-Speaking Latina/o adults with chronic insomnia.